

疾病、傷害及び死因の統計分類提要 ICD-10（2013年版）準拠の修正該当箇所のWHO原文

Updates 3 & 4 in relation to COVID-19 coding in ICD-10

A set of additional categories has been agreed to be able to document or flag presentation for:

- conditions that occur in the context of COVID-19
- immunization to prevent COVID-19 and,
- an adverse reaction to a COVID-19 vaccine.

Both three-character and four-character codes have been defined to respond to the different levels of coding depth that is in place in different countries. ¹

Provisional assignment of new diseases of uncertain etiology or emergency use (U00-U49)

U08 Personal history of COVID-19

U08.9 Personal history of COVID-19, unspecified

Note: This optional code is used to record an earlier episode of COVID-19, confirmed or probable that influences the person's health status, and the person no longer suffers of COVID-19. This code should not be used for primary mortality tabulation.

U09 Post COVID-19 condition

U09.9 Post COVID-19 condition, unspecified

Note: This optional code serves to allow the establishment of a link with COVID-19. This code is not to be used in cases that still are presenting COVID-19.

U10 Multisystem inflammatory syndrome associated with COVID-19

U10.9 Multisystem inflammatory syndrome associated with COVID-19, unspecified

Cytokine storm
Kawasaki-like syndrome
Paediatric Inflammatory Multisystem Syndrome (PIMS)
Multisystem Inflammatory Syndrome in Children (MIS-C)

Temporally associated
with COVID-19

Excludes: Mucocutaneous lymph node syndrome [Kawasaki] (M30.3)

¹ It is further noted that technological constraints may require bridge national coding to the international codes until an update of the relevant IT systems allows use of the international codes.

U11 Need for immunization against COVID-19

U11.9 Need for immunization against COVID-19, unspecified

Note: This code should not be used for international comparison or for primary mortality coding. This optional code is intended to be used when a person who may or may not be sick encounters health services for the specific purpose of receiving a COVID-19 vaccine.

Prophylactic COVID-19 vaccination

Excludes: immunization not carried out (Z28.-)

U12 COVID-19 vaccines causing adverse effects in therapeutic use

U12.9 COVID-19 vaccines causing adverse effects in therapeutic use, unspecified

Note: This code is to be used as an external cause code (i.e. as a subcategory under Y59 *Other and unspecified vaccines and biological substances*). In addition to this, a code from another chapter of the classification should be used indicating the nature of the adverse effect.

Correct administration of COVID-19 vaccine in prophylactic therapeutic use as the cause of any adverse effect.

Instruction	Tabular list entries	Source	Date approved	Major / Minor update	Suggested implementation date
Add excludes notes	<p>B34.2 Coronavirus infection, unspecified site <i>Excl:</i> COVID-19, virus identified(U07.1) COVID-19, virus not identifiedU07.2) severe acute respiratory syndrome[SARS](U04.9)</p>	WHO	April 2020	Major	Immediate
Add excludes notes	<p>U04.9 Severe acute respiratory syndrome [SARS], unspecified <i>Excl:</i> COVID-19, virus identified(U07.1) COVID-19, virus not identified(U07.2)</p>	WHO	April 2020	Major	Immediate
Revise category title and code title	<p>U08 Emergency use of U08 Personal history of COVID-19 U08.9 Personal history of COVID-19, unspecified This optional code is used to record an earlier episode of COVID-19, confirmed or probable that influences the person's health status, and the person no longer suffers of COVID-19. This code should not be used for primary mortality tabulation.</p>	WHO	September 2020	Major	Immediate
Revise category title and code title	<p>U09 Emergency use of U09 Post COVID-19 condition U09.9 Post COVID-19 condition, unspecified This optional code serves to allow the establishment of a link with COVID-19. This code is not to be used in cases that still are presenting COVID-19.</p>	WHO	September 2020	Major	Immediate
Revise category title and code title	<p>U10 Emergency use of U10 Multisystem inflammatory syndrome associated with COVID-19 U10.9 Multisystem inflammatory syndrome associated with COVID-19, unspecified Cytokine storm Kawasaki-like syndrome Paediatric Inflammatory Multisystem Syndrome(PIMS) Multisystem Inflammatory Syndrome in Children(MIS-C) <i>Excl:</i> Mucocutaneous lymph node syndrome [Kawasaki](M30.3)</p> <p style="text-align: right;">Temporally associated with COVID-19</p>	WHO	September 2020	Major	Immediate

Instruction	Tabular list entries	Source	Date approved	Major / Minor update	Suggested implementation date
Revise category title and code title	<p><u>U11 Emergency use of U11 Need for immunization against COVID-19</u> <u>U11.9 Need for immunization against COVID-19, unspecified</u> <u>This code should not be used for international comparison or for primary mortality coding.</u> <u>This optional code is intended to be used when a person who may or may not be sick encounters health services for the specific purpose of receiving a COVID-19 vaccine.</u></p> <p><u>Prophylactic COVID-19 vaccination</u></p> <p><u>Exc/: immunization not carried out(Z28.-)</u></p>	WHO	January 2021	Major	Immediate
Revise category title and code title	<p><u>U12 Emergency use of U12 COVID-19 vaccines causing adverse effects in therapeutic use</u> <u>U12.9 COVID-19 vaccines causing adverse effects in therapeutic use, unspecified</u></p> <p><u>This code is to be used as an external cause code (i.e. as a subcategory under Y59 Other and unspecified vaccines and biological substances). In addition to this, a code from another chapter of the classification should be used indicating the nature of the adverse effect.</u></p> <p><u>Correct administration of COVID-19 vaccine in prophylactic therapeutic use as the cause of any adverse effect.</u></p>	WHO	January 2021	Major	Immediate

Instruction	Alphabetic Index entries	Source URC#	Date approved	Major / Minor update	Suggested implementation date
Add subterms	<p>History(personal)(of) - chromosomal abnormality Z87.7 - congenital malformation Z87.7 - contraception Z92.0 - COVID-19 U08.9 -disease or disorder (of) Z87.8 --blood and blood-forming organs Z86.2 --circulatory system Z86.7 --COVID-19 U08.9 --digestive system </p>	WHO	September 2020		Immediate
Add lead term	<p>Positive - culture - VDRL -- with signs or symptoms - <i>code as</i> Syphilis, by site and stage -- false R76.2 Post COVID-19 condition U09.9 Postcardiotomy syndrome I97.0</p>	WHO	September 2020		Immediate
Add subterms	<p>Syndrome - see also Disease - 5q-minus (related to alkylating agent)(related to Epipodophyllotoxin)(related to therapy) D46.6 - multiple operations F68.1 - Multisystem inflammatory associated with COVID-19 U10.9 - myasthenic (in) G70.9 -- diabetes mellitus - code to E10-E14 </p>	WHO	September 2020		Immediate

Instruction	Alphabetic Index entries	Source URC#	Date approved	Major / Minor update	Suggested implementation date
Add subterms	<p>Vaccination</p> <p>.....</p> <p>- prophylactic (against) Z26.9</p> <p>-- arthropod-borne viral encephalitis Z24.1</p> <p>-- cholera (alone) Z23.0</p> <p>---with typhoid-paratyphoid (cholera + TAB) Z27.0</p> <p>--common cold Z25.8</p> <p>--COVID-19 U11.9</p> <p>--diphtheria (alone) Z23.6</p>	WHO	January 2021		Immediate

Instruction	Table of Drugs and Chemicals	Source URC#	Date approved	Major / Minor update	Suggested implementation date																																										
Add subterm	<table border="0"> <tr> <td></td> <td colspan="3">Poisoning</td> <td></td> <td>Adverse effect</td> </tr> <tr> <td>Substance</td> <td>Chapter XIX</td> <td>Accidental</td> <td>Intentional self-harm</td> <td>Undetermined intent</td> <td>in therapeutic use</td> </tr> <tr> <td>.....</td> <td></td> <td></td> <td></td> <td></td> <td></td> </tr> <tr> <td>Coumetarol</td> <td>T45.5</td> <td>X44</td> <td>X64</td> <td>Y14</td> <td>Y44.2</td> </tr> <tr> <td>COVID-19 vaccine (NEC)</td> <td></td> <td></td> <td></td> <td></td> <td>U12.9</td> </tr> <tr> <td>Crataegus extract</td> <td>T46.0</td> <td>X44</td> <td>X64</td> <td>Y14</td> <td>Y52.0</td> </tr> <tr> <td>.....</td> <td></td> <td></td> <td></td> <td></td> <td></td> </tr> </table>		Poisoning				Adverse effect	Substance	Chapter XIX	Accidental	Intentional self-harm	Undetermined intent	in therapeutic use						Coumetarol	T45.5	X44	X64	Y14	Y44.2	COVID-19 vaccine (NEC)					U12.9	Crataegus extract	T46.0	X44	X64	Y14	Y52.0						WHO	January 2021		Immediate
	Poisoning				Adverse effect																																										
Substance	Chapter XIX	Accidental	Intentional self-harm	Undetermined intent	in therapeutic use																																										
.....																																															
Coumetarol	T45.5	X44	X64	Y14	Y44.2																																										
COVID-19 vaccine (NEC)					U12.9																																										
Crataegus extract	T46.0	X44	X64	Y14	Y52.0																																										
.....																																															